Skip to main content
Top
Published in: Pediatric Surgery International 1/2011

01-01-2011 | Original Article

Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT

Authors: Tomoro Hishiki, Tadashi Matsunaga, Fumiaki Sasaki, Michihiro Yano, Kohmei Ida, Hiroshi Horie, Satoshi Kondo, Ken-Ichiro Watanabe, Takaharu Oue, Tatsuro Tajiri, Arata Kamimatsuse, Naomi Ohnuma, Eiso Hiyama

Published in: Pediatric Surgery International | Issue 1/2011

Login to get access

Abstract

Background

In the recent years, surgical resection with pre- and/or postoperative chemotherapy has markedly improved the survival rate of hepatoblastoma patients. We herein report the results of patients treated with the current protocol of the Japanese Study Group for Pediatric Liver Tumor, JPLT-2.

Methods

A total of 279 patients with malignant liver tumor were enrolled in JPLT-2. Data from 212 hepatoblastoma cases were analyzed. PRETEXT I patients were treated with primary resection followed by low doses of cisplatin–pirarubicin (tetrahydropyranyl-adriamycin). Otherwise, patients received preoperative cisplatin–pirarubicin (CITA), followed by surgery and postoperative chemotherapy. Ifosfamide, pirarubicin, etoposide, and carboplatin (ITEC) were given as a salvage treatment. High-dose chemotherapy with hematopoietic stem cell transplantation (SCT) was reserved for patients with metastatic diseases.

Results

The 5-year overall survival rate (OS) in non-metastatic cases was 100% for PRETEXT I, 87.1% for PRETEXT II, 89.7% for PRETEXT III, and 78.3% for PRETEXT IV. The 5-year OS in metastatic cases was 43.9%. The outcome in non-metastatic PRETEXT IV cases was markedly improved, while the results of metastatic tumors remained poor.

Conclusions

JPLT-2 protocol achieved satisfactory survival among children with non-metastatic hepatoblastoma. New approaches are needed for patients with metastatic diseases.
Literature
1.
go back to reference Ortega JA, Douglass EC, Feusner JH et al (2000) Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 18:2665–2675PubMed Ortega JA, Douglass EC, Feusner JH et al (2000) Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 18:2665–2675PubMed
2.
go back to reference Fuchs J, Rydzynski J, von Shweinitz D et al (2002) Pretreatment prognostic factors and treatment results in children with hepatoblastoma. A report from the German Cooperative Pediatric Liver Tumour Study HB94. Cancer 95:172–182CrossRefPubMed Fuchs J, Rydzynski J, von Shweinitz D et al (2002) Pretreatment prognostic factors and treatment results in children with hepatoblastoma. A report from the German Cooperative Pediatric Liver Tumour Study HB94. Cancer 95:172–182CrossRefPubMed
3.
go back to reference Perilongo G, Shafford E, Maibach R et al (2004) Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology––SIOPEL 2. Eur J Cancer 40:411–421CrossRefPubMed Perilongo G, Shafford E, Maibach R et al (2004) Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology––SIOPEL 2. Eur J Cancer 40:411–421CrossRefPubMed
4.
go back to reference Sasaki F, Matsunaga T, Iwafuchi M et al (2002) Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 37:851–856CrossRefPubMed Sasaki F, Matsunaga T, Iwafuchi M et al (2002) Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 37:851–856CrossRefPubMed
5.
go back to reference Katzenstein HM, London WB, Douglass EC et al (2002) Treatment of unresectable and metastatic hepatoblastoma: a Pediatric Oncology Group Phase II Study. J Clin Oncol 20:3438–3444CrossRefPubMed Katzenstein HM, London WB, Douglass EC et al (2002) Treatment of unresectable and metastatic hepatoblastoma: a Pediatric Oncology Group Phase II Study. J Clin Oncol 20:3438–3444CrossRefPubMed
6.
go back to reference Matsunaga T, Sasaki F, Ohira M et al (2003) Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int 19:142–146PubMed Matsunaga T, Sasaki F, Ohira M et al (2003) Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int 19:142–146PubMed
7.
go back to reference Malogolowkin MH, Katzenstein H, Krailo MD et al (2006) Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 24:2879–2884CrossRefPubMed Malogolowkin MH, Katzenstein H, Krailo MD et al (2006) Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 24:2879–2884CrossRefPubMed
8.
go back to reference Czauderna P, Otte JB, Aronson DC et al (2005) Guidelines for surgical treatment of hepatoblastoma in the modern era––recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 41:1031–1036CrossRefPubMed Czauderna P, Otte JB, Aronson DC et al (2005) Guidelines for surgical treatment of hepatoblastoma in the modern era––recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 41:1031–1036CrossRefPubMed
9.
go back to reference Tagge EP, Tagge DU, Reyes J et al (1992) Resection, including transplantation, for hepatoblastoma and hepatocellular carcinoma: impact on survival. J Pediatr Surg 27:292–297CrossRefPubMed Tagge EP, Tagge DU, Reyes J et al (1992) Resection, including transplantation, for hepatoblastoma and hepatocellular carcinoma: impact on survival. J Pediatr Surg 27:292–297CrossRefPubMed
10.
go back to reference King DR, Ortega J, Campbell J et al (1991) The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy. J Pediatr Surg 26:1074–1081CrossRefPubMed King DR, Ortega J, Campbell J et al (1991) The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy. J Pediatr Surg 26:1074–1081CrossRefPubMed
11.
go back to reference Perilongo G, Maibach R, Shafford E et al (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361:1662–1670CrossRefPubMed Perilongo G, Maibach R, Shafford E et al (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361:1662–1670CrossRefPubMed
12.
go back to reference Brown J, Perilongo G, Shafford E et al (2000) Pretreatment prognostic factors for children with hepatoblatoma––results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1. Eur J Cancer 36:1418–1425CrossRefPubMed Brown J, Perilongo G, Shafford E et al (2000) Pretreatment prognostic factors for children with hepatoblatoma––results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1. Eur J Cancer 36:1418–1425CrossRefPubMed
13.
go back to reference Aronson DC, Schnater JM, Staalman CR et al (2005) Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Grou p SIOPEL-1 study. J Clin Oncol 23:1245–1252CrossRefPubMed Aronson DC, Schnater JM, Staalman CR et al (2005) Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Grou p SIOPEL-1 study. J Clin Oncol 23:1245–1252CrossRefPubMed
14.
go back to reference Meyers RL, Rowland JR, Krailo M et al (2009) Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 53:1016–1022CrossRefPubMed Meyers RL, Rowland JR, Krailo M et al (2009) Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 53:1016–1022CrossRefPubMed
15.
go back to reference Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, Takahashi H (2002) Apoptosis in young rats with adriamycin-induced cardiomyopathy––comparison with pirarubicin, a new anthracycline derivative. Pediatr Res 51:256–259CrossRefPubMed Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, Takahashi H (2002) Apoptosis in young rats with adriamycin-induced cardiomyopathy––comparison with pirarubicin, a new anthracycline derivative. Pediatr Res 51:256–259CrossRefPubMed
16.
go back to reference Zsíros J, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28:2584–2590CrossRefPubMed Zsíros J, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28:2584–2590CrossRefPubMed
17.
go back to reference Otte JB, Oritchars J, Aronson DC et al (2004) Liver transplantation for hepatoblastoma: results from the international society of pediatric oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 42:74–83CrossRefPubMed Otte JB, Oritchars J, Aronson DC et al (2004) Liver transplantation for hepatoblastoma: results from the international society of pediatric oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 42:74–83CrossRefPubMed
18.
go back to reference Otte JB, de Goyet JV, Reding R (2005) Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant 9:557–565CrossRefPubMed Otte JB, de Goyet JV, Reding R (2005) Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant 9:557–565CrossRefPubMed
19.
go back to reference Reyes JD, Carr B, Dvorchik I et al (2000) Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 136:795–804CrossRefPubMed Reyes JD, Carr B, Dvorchik I et al (2000) Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 136:795–804CrossRefPubMed
20.
go back to reference Tanaka K, Uemoto S, Tokunaga Y et al (1993) Surgical techniques and innovations in living related liver transplantation. Ann Surg 217:82–91CrossRefPubMed Tanaka K, Uemoto S, Tokunaga Y et al (1993) Surgical techniques and innovations in living related liver transplantation. Ann Surg 217:82–91CrossRefPubMed
21.
go back to reference Kasahara M, Ueda M, Haga H et al (2005) Living-donor liver transplantation for hepatoblastoma. Am J Transplant 5:2229–2235CrossRefPubMed Kasahara M, Ueda M, Haga H et al (2005) Living-donor liver transplantation for hepatoblastoma. Am J Transplant 5:2229–2235CrossRefPubMed
22.
go back to reference Nishimura S, Sato T, Fujita N et al (2002) High-dose chemotherapy in children with metastatic hepatoblastoma. Pediatr Int 44:300–305CrossRefPubMed Nishimura S, Sato T, Fujita N et al (2002) High-dose chemotherapy in children with metastatic hepatoblastoma. Pediatr Int 44:300–305CrossRefPubMed
23.
go back to reference Yoshinari M, Imaizumi M, Hayashi Y et al (1998) Peripheral blood stem cell transplantation for hepatoblastoma with microscopical residue: a therapeutic approach for incompletely resected tumor. Tohoku J Exp Med 184:247–254CrossRefPubMed Yoshinari M, Imaizumi M, Hayashi Y et al (1998) Peripheral blood stem cell transplantation for hepatoblastoma with microscopical residue: a therapeutic approach for incompletely resected tumor. Tohoku J Exp Med 184:247–254CrossRefPubMed
24.
go back to reference Kitahara S, Makuuchi M, Ishizone S et al (1995) Successful left trisegmentectomy for ruptured hepatoblastoma using intraoperative transarterial embolization. J Pediatr Surg 30:1709–1712CrossRefPubMed Kitahara S, Makuuchi M, Ishizone S et al (1995) Successful left trisegmentectomy for ruptured hepatoblastoma using intraoperative transarterial embolization. J Pediatr Surg 30:1709–1712CrossRefPubMed
25.
go back to reference Iida T, Senaga M, Takeuchi Y et al (2004) Successful resection of a ruptured hepatoblastoma prior to chemotherapy: report of a case. Surg Today 34:710–714CrossRefPubMed Iida T, Senaga M, Takeuchi Y et al (2004) Successful resection of a ruptured hepatoblastoma prior to chemotherapy: report of a case. Surg Today 34:710–714CrossRefPubMed
26.
go back to reference Hara J, Osugi Y, Ohta H et al (1998) Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric tumors. Bone Marrow Transplant 22:7–12CrossRefPubMed Hara J, Osugi Y, Ohta H et al (1998) Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric tumors. Bone Marrow Transplant 22:7–12CrossRefPubMed
27.
go back to reference Suita S, Tajiri T, Takamatsu H et al (2004) Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen––a report from the study group for pediatric solid malignant tumors in the Kyushu area. J Pediatr Surg 39:195–198CrossRefPubMed Suita S, Tajiri T, Takamatsu H et al (2004) Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen––a report from the study group for pediatric solid malignant tumors in the Kyushu area. J Pediatr Surg 39:195–198CrossRefPubMed
28.
go back to reference von Schweinitz D, Hecker H, Harmas D et al (1995) Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma––a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 30:845–852CrossRef von Schweinitz D, Hecker H, Harmas D et al (1995) Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma––a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 30:845–852CrossRef
29.
go back to reference Katzenstein HM, Rigsby C, Shaw PH et al (2002) Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol 24:751–755CrossRefPubMed Katzenstein HM, Rigsby C, Shaw PH et al (2002) Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol 24:751–755CrossRefPubMed
30.
go back to reference Palmer RD, Williams DM (2003) Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). Med Pediatr Oncol 41:78–80CrossRefPubMed Palmer RD, Williams DM (2003) Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). Med Pediatr Oncol 41:78–80CrossRefPubMed
31.
go back to reference Ijichi O, Ishikawa S, Shinkoda Y et al (2006) Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan. Pediatr Transplant 10(5):635–638CrossRefPubMed Ijichi O, Ishikawa S, Shinkoda Y et al (2006) Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan. Pediatr Transplant 10(5):635–638CrossRefPubMed
32.
go back to reference Bomgaars LR, Bernstein M, Krailo M et al (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 25:4622–4627CrossRefPubMed Bomgaars LR, Bernstein M, Krailo M et al (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 25:4622–4627CrossRefPubMed
33.
go back to reference Qayed M, Powell C, Morgan ER et al (2010) Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer 54:761–763PubMed Qayed M, Powell C, Morgan ER et al (2010) Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer 54:761–763PubMed
Metadata
Title
Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT
Authors
Tomoro Hishiki
Tadashi Matsunaga
Fumiaki Sasaki
Michihiro Yano
Kohmei Ida
Hiroshi Horie
Satoshi Kondo
Ken-Ichiro Watanabe
Takaharu Oue
Tatsuro Tajiri
Arata Kamimatsuse
Naomi Ohnuma
Eiso Hiyama
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Pediatric Surgery International / Issue 1/2011
Print ISSN: 0179-0358
Electronic ISSN: 1437-9813
DOI
https://doi.org/10.1007/s00383-010-2708-0

Other articles of this Issue 1/2011

Pediatric Surgery International 1/2011 Go to the issue